Mallone Roberto, Kochik Sharon A, Reijonen Helena, Carson Bryan, Ziegler Steven F, Kwok William W, Nepom Gerald T
Benaroya Research Institute at Virginia Mason, 1201 Ninth Ave, Seattle, WA 98101, USA.
Blood. 2005 Oct 15;106(8):2798-805. doi: 10.1182/blood-2004-12-4848. Epub 2005 Jul 19.
Major histocompatibility complex class II tetramer staining and activation analysis identified 2 distinct types of antigen-specific CD4+ T cells in the peripheral blood of humans with type 1 (autoimmune) diabetes. T cells with low-avidity recognition of peptide-MHC ligands had low sensitivity to activation and inefficient activation-induced apoptosis. In contrast, high-avidity T cells were highly sensitive to antigen-induced cell death through apoptotic mechanisms, and both apoptosis-resistant high- and low-avidity T cells that survived prolonged tetramer treatment were rendered anergic to restimulation by antigen. In addition, however, apoptosis-resistant high-avidity T cells acquired regulatory features, being able to suppress both antigen-specific and nonspecific CD4+ T-cell responses. This suppression was contact-dependent and correlated with the down-regulation of HLA class II and costimulatory molecules on antigen-presenting cells, including B cells and dendritic cells. T cells face a variety of fates following antigen exposure, including the paradoxic maintenance of high-avidity autoreactive T cells in the peripheral circulation, perhaps due to this capability of acquiring anergic and suppressive properties. Regulation via down-modulation of antigen-presenting cell function, a form of cell-to-cell licensing for suppression, also offers possibilities for the application of peptide-MHC therapeutics.
主要组织相容性复合体II类四聚体染色及活化分析在1型(自身免疫性)糖尿病患者外周血中鉴定出两种不同类型的抗原特异性CD4 + T细胞。对肽 - MHC配体低亲和力识别的T细胞对活化敏感性低,活化诱导的凋亡效率低。相比之下,高亲和力T细胞通过凋亡机制对抗原诱导的细胞死亡高度敏感,并且在长时间四聚体处理后存活的抗凋亡高亲和力和低亲和力T细胞对抗原再刺激均无反应。然而,此外,抗凋亡高亲和力T细胞获得了调节特性,能够抑制抗原特异性和非特异性CD4 + T细胞反应。这种抑制是接触依赖性的,并且与抗原呈递细胞(包括B细胞和树突状细胞)上HLA II类分子和共刺激分子的下调相关。抗原暴露后T细胞面临多种命运,包括外周循环中高亲和力自身反应性T细胞的反常维持,这可能归因于其获得无反应性和抑制特性的能力。通过下调抗原呈递细胞功能进行调节,这是一种用于抑制的细胞间许可形式,也为肽 - MHC疗法的应用提供了可能性。